Foxo1 in Apoliprotein C-III & Triglyceride Metabolism
Foxo1 in Apoliprotein C-III & Triglyceride Metabolism
批准号:
7225995
负责人:
HENGJIANG HENRY DONG
金额:
$25.78万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-01 至 2011-04-30
关键词:
AddressApolipoproteins CAtherosclerosisBiological AssayCatabolismComplementary DNACoronary ArteriosclerosisCouplingDevelopmentDiabetic mouseDominant-Negative MutationFunctional disorderGene ExpressionGene TransferGenesGoalsHepaticHepatocyteHydrolysisHypertriglyceridemiaInsulinInsulin ResistanceKnockout MiceLightLinkLiverLuciferasesMediatingMolecularMusNon-Insulin-Dependent Diabetes MellitusObesityPathogenesisPhysiologicalPlasmaPlayProductionRateRegulationReporterResearch PersonnelRisk FactorsRoleSignal TransductionSiteSystemTestingTransgenic MiceTransgenic OrganismsTriglyceride MetabolismTriglyceridesVery low density lipoproteinapolipoprotein C-IIIbasechromatin immunoprecipitationdb/db mousediabeticgain of functionimprovedlipid disorderloss of functionmicrosomal triglyceride transfer proteinprogramspromoterprotein expressionprotein functionresponsetranscription factorvery low density lipoprotein triglyceride
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Hypertriglyceridemia is the commonest lipid disorder associated with insulin resistance and type 2 diabetes. It is characterized by increased production and decreased clearance of triglyceride (TG)-rich very low-density lipoproteins (VLDL). Hypertriglyceridemia is a major risk factor for the pathogenesis of atherosclerosis and coronary artery disease, but its pathophysiology is poorly understood. Our long-term goal is to understand why insulin resistance causes abnormal VLDL-TG metabolism and results in the development of hypertriglyceridemia in insulin resistant subjects with obesity and type 2 diabetes. Foxol is a transcription factor that plays a key role in mediating insulin action on gene expression. We have shown that Foxol regulates hepatic expression of apolipoprotein C-III (apoC-III) and microsomal triglyceride transfer protein (MTP), two rate-limiting steps in VLDL-TG metabolism. ApoC-III acts to regulate VLDL-TG hydrolysis and clearance, whereas MTP functions to control VLDL assembly and secretion. Both genes are physiologically suppressed by insulin, and are abnormally elevated in response to insulin resistance. We seek to test the hypothesis that the aberrant expression of apoC-III and MTP is due to excessive Foxol activity, resulting from insulin resistance. We propose three specific aims: 1) To determine whether Foxol mediates insulin action on VLDL-TG metabolism in normal and diabetic mice; 2) To determine whether Foxol plays a role in linking insulin resistance to apoC-III overproduction in the pathogenesis of hypertriglyceridemia; 3) To elucidate the role of Foxol signaling through MTP in the pathogenesis of hepatic VLDL-TG overproduction in hypertriglyceridemia. To address these specific aims, we will employ gene transfer and transgenic approaches to achieve gain- vs. loss-of-function of Foxol in cultured hepatocytes as well as in livers of mice with impaired insulin action and/or altered TG metabolism. These studies will help define the mechanism of insulin-dependent regulation of MTP and apoC-III production, and elucidate the molecular links between insulin resistance and hypertriglyceridemia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FoxO1 in Gestational Diabetes
-
批准号:10263260
-
项目类别:
-
资助金额:$38.96万
-
财政年份:2020
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
FoxO1 in Gestational Diabetes
-
批准号:10118363
-
项目类别:
-
资助金额:$38.95万
-
财政年份:2020
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
FoxO1 in Gestational Diabetes
-
批准号:10656362
-
项目类别:
-
资助金额:$39.61万
-
财政年份:2020
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
FoxO1 in Gestational Diabetes
-
批准号:10418783
-
项目类别:
-
资助金额:$39.6万
-
财政年份:2020
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Myeloid FoxO1 in Lipid Metabolism
-
批准号:10459447
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2019
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Myeloid FoxO1 in Lipid Metabolism
-
批准号:10220965
-
项目类别:
-
资助金额:$39.39万
-
财政年份:2019
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Fox01 in Beta-Cell Compensation
-
批准号:8975768
-
项目类别:
-
资助金额:$33.89万
-
财政年份:2014
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Fox01 in Beta-Cell Compensation
-
批准号:9187796
-
项目类别:
-
资助金额:$33.89万
-
财政年份:2014
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Fox01 in Beta-Cell Compensation
-
批准号:8629313
-
项目类别:
-
资助金额:$35.05万
-
财政年份:2014
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Fox01 in Beta-Cell Compensation
-
批准号:8791685
-
项目类别:
-
资助金额:$33.89万
-
财政年份:2014
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
FoxO6 in Glucose Metabolism
-
批准号:8310118
-
项目类别:
-
资助金额:$31.12万
-
财政年份:2010
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
FoxO6 in Glucose Metabolism
-
批准号:8147834
-
项目类别:
-
资助金额:$31.12万
-
财政年份:2010
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
FoxO6 in Glucose Metabolism
-
批准号:8492080
-
项目类别:
-
资助金额:$30.03万
-
财政年份:2010
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
FoxO6 in Glucose Metabolism
-
批准号:8038039
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2010
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Foxo1 in Triglyceride Metabolism
-
批准号:7406053
-
项目类别:
-
资助金额:$25.26万
-
财政年份:2006
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Foxo1 in Triglyceride Metabolism
-
批准号:7841916
-
项目类别:
-
资助金额:$26.4万
-
财政年份:2006
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Foxo1 in Triglyceride Metabolism
-
批准号:7097070
-
项目类别:
-
资助金额:$26.55万
-
财政年份:2006
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Foxo1 in Triglyceride Metabolism
-
批准号:7777467
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2006
-
负责人:HENGJIANG HENRY DONG
-
依托单位:
Foxo1 in Triglyceride Metabolism
-
批准号:7586062
-
项目类别:
-
资助金额:$26.67万
-
财政年份:2006
-
负责人:HENGJIANG HENRY DONG
-
依托单位: